Phase 3 Breast Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with triple-negative breast cancer (TNBC), confirmed through a tissue or cell sample test.
• People whose cancer has either spread from the start (de novo metastatic) or has come back at least 6 months after finishing treatment that was intended to cure it.
• People who have not yet received any systemic (whole-body) anti-cancer treatment for cancer that has spread or cannot be surgically removed.
• People whose tumour tests negative for a protein called PD-L1, or whose tumour tests positive for PD-L1 but whose cancer returned after receiving a specific type of immunotherapy (anti-PD-1/PD-L1 treatment) for early-stage disease.
• People who have at least one tumour that can be measured using standard imaging criteria.
• People who are in good enough general health to carry out normal daily activities, with no decline in health in the 2 weeks before joining the trial (measured on a standard scale called ECOG, scored 0 or 1).
• People who have a life expectancy of at least 3 months.
• People whose treating doctor considers them suitable to receive at least one of the chemotherapy options listed in the trial (paclitaxel, nab-paclitaxel, capecitabine, eribulin, or carboplatin).
• People whose liver, kidneys, bone marrow, and other organs are functioning well enough to meet the trial's health requirements.

Who may not be able to join:

• People who currently have another active cancer.
• People with significant or uncontrolled heart or blood vessel disease.
• People who have had a history of lung inflammation (pneumonitis) or scarring lung disease (interstitial lung disease) not caused by infection that required steroid treatment, or who currently have either of these conditions.
• People who have had an active infection requiring treatment with medicines taken throughout the body within 2 weeks before joining the trial.
• People with an active hepatitis B or hepatitis C infection.
• People who are HIV-positive, have a history of AIDS, or have a known active syphilis infection.
• People who have a known allergy or sensitivity to the study drug (SKB264) or any of its ingredients.
• People who have previously received a treatment that targets a protein called TROP2, or who have previously received a type of chemotherapy called a topoisomerase 1 inhibitor.
• People who have previously received the same chemotherapy that would be assigned to them in this trial (with the exception of taxane-based chemotherapy).
• People who are pregnant or currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.